Hydroquinone
Tri-luma (hydroquinone) is a small molecule pharmaceutical. Hydroquinone was first approved as Tri-luma on 2002-01-18. It is used to treat hyperpigmentation in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Combinations
Tri-luma
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fluocinolone acetonide
+
Hydroquinone
+
Tretinoin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRI-LUMA | Galderma | N-021112 RX | 2002-01-18 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| hydroquinone 4% | unapproved drug other | 2023-06-05 |
| tri-luma | New Drug Application | 2019-06-05 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hyperpigmentation | — | D017495 | — |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
178 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | 5 | 4 | 14 | 13 | 8 | 44 |
| Postoperative pain | D010149 | G89.18 | — | 4 | 2 | 18 | 5 | 29 | |
| Acute pain | D059787 | R52 | 2 | 4 | 5 | 3 | 2 | 15 | |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 5 | 4 | 1 | 1 | 3 | 13 |
| Healthy volunteers/patients | — | 4 | — | — | 2 | 1 | 7 | ||
| Cancer pain | D000072716 | G89.3 | — | 2 | 2 | 2 | 1 | 7 | |
| Neoplasms | D009369 | C80 | — | 1 | 2 | 2 | 1 | 6 | |
| Analgesia | D000698 | 2 | 2 | 1 | 1 | — | 6 | ||
| Low back pain | D017116 | HP_0003419 | M54.5 | — | 1 | 2 | 1 | 1 | 5 |
| Cesarean section | D002585 | 1 | 1 | — | 2 | — | 4 |
Show 31 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic pain | D059350 | HP_0012532 | 1 | — | 4 | — | — | 5 | |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | 3 | — | — | 3 |
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | — | 3 | — | — | 3 |
| Heroin dependence | D006556 | EFO_0004240 | — | — | 1 | — | 2 | 3 | |
| Cystectomy | D015653 | — | — | 1 | — | — | 1 | ||
| Multiple trauma | D009104 | T07 | — | — | 1 | — | — | 1 | |
| Back pain | D001416 | HP_0003418 | M54 | — | — | 1 | — | — | 1 |
| Mucositis | D052016 | EFO_1001898 | — | — | 1 | — | — | 1 | |
| Prostatic neoplasms | D011471 | C61 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 1 | 1 | — | — | — | 2 |
| Tonsillitis | D014069 | HP_0011110 | J03 | 1 | 1 | — | — | — | 2 |
| Orthopedic procedures | D019637 | — | 1 | — | — | — | 1 | ||
| Wound healing | D014945 | GO_0042060 | 1 | 1 | — | — | — | 1 | |
| Procedural pain | D000073818 | — | 1 | — | — | — | 1 | ||
| Rectal diseases | D012002 | — | 1 | — | — | — | 1 | ||
| Extracorporeal membrane oxygenation | D015199 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nerve block | D009407 | — | — | — | — | 1 | 1 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | — | 1 | 1 |
| Hepatectomy | D006498 | — | — | — | — | 1 | 1 | ||
| Epidural analgesia | D015360 | — | — | — | — | 1 | 1 | ||
| Pain measurement | D010147 | — | — | — | — | 1 | 1 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | — | 1 | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | — | — | 1 | 1 | |
| Sarcoma | D012509 | — | — | — | — | 1 | 1 | ||
| Fallopian tube neoplasms | D005185 | — | — | — | — | 1 | 1 | ||
| Uterine cervical neoplasms | D002583 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | HYDROQUINONE |
| INN | — |
| Description | Hydroquinone is a benzenediol comprising benzene core carrying two hydroxy substituents para to each other. It has a role as a cofactor, a carcinogenic agent, an Escherichia coli metabolite, a human xenobiotic metabolite, a skin lightening agent, an antioxidant and a mouse metabolite. It is a benzenediol and a member of hydroquinones. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Oc1ccc(O)cc1 |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,592 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
61,514 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more